The Exploration of Protein Therapies for the Alzheimers Disease

Abstract

Alzheimer’s disease (AD) is a global puzzle that first appeared in 1901, the number of patients with AD is soaring all over the world these years. While various mechanisms were proposed, such as Aβ cascade hypothesis, the results were still dissatisfactory, and they all seem to be implicated in each other. Until now, only two kinds of medicines are allowed to treat AD by the FDA, but they are not capable of achieving therapeutic effects. New attention is paid to the treatment options for lipids. This paper analyzes references about cholesterol homeostasis and transport in the brain, finding that an excellent curative effect can emerge by intraperitoneal injection of CS-6253 to raise the level of lipidation of APOE 4, which can provide the references on protein therapies and lipids mechanism for AD, promoting the proceeding of AD study. Nevertheless, the topic that make CS-6253 cross the BBB and perform effectively in the human body have not been tackled, further studies can be biased toward this aspect.